Tower Research Capital (TRC)’s Calidi Biotherapeutics CLDI Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237	Hold	87	–	–	﹤0.01%	5092
2026 Q1	$333	Sell	87 -86	-50%	-$1.03K	﹤0.01%	4908
2025 Q4	$3.25K	Buy	+173	New	+$4.07K	﹤0.01%	4396
2025 Q3	–	Sell	-47	Closed	-$2.06K	–	5260
2025 Q2	$2.06K	Buy	47 +20	+74%	+$1.55K	﹤0.01%	4707
2025 Q1	$2.9K	Buy	+27	New	+$4.92K	﹤0.01%	4491
2024 Q4	–	Sell	-19	Closed	-$4.18K	–	5720
2024 Q3	$4.18K	Buy	19 +15	+375%	+$4.18K	﹤0.01%	4644
2024 Q2	$1.68K	Sell	4 -5	-56%	-$2.56K	﹤0.01%	5107
2024 Q1	$9.99K	Buy	+9	New	+$14.7K	﹤0.01%	3766
2023 Q4	–	Hold	0	–	–	–	5881

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Tower Research Capital (TRC)'s CLDI Position: Q2 2026 in Review

Tower Research Capital (TRC) held its Calidi Biotherapeutics (CLDI) position steady in Q2 2026 at 87 shares worth $237. The position accounts for ﹤0.01% of the portfolio, ranked #5092.

Tower Research Capital (TRC) first reported a position in CLDI in Q1 2024 and has held it in 8 quarters since. The position peaked at $9.99K in Q1 2024. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

Tower Research Capital (TRC) held 87 shares of Calidi Biotherapeutics worth $237 as of Q2 2026.
Tower Research Capital (TRC) left its Calidi Biotherapeutics share count unchanged in Q2 2026.
Calidi Biotherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #5092 holding.
Tower Research Capital (TRC) first reported a position in Calidi Biotherapeutics in Q1 2024 and has held it in 8 quarters since.
Tower Research Capital (TRC)'s Calidi Biotherapeutics position peaked at $9.99K in Q1 2024.
22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.